

BRIXADI:



FDA Approved New Long-Acting Buprenorphine for Opioid Use Disorder





Brixadi



- How to Dose
 - Injection Sites
 - How to Switch?
 - Discontinuation



- Common Adverse Reactions
- Warnings & Precautions









Harvinder Singh, MD | Psychiatry Education Forum Academy



NO DISCLOSURES



INDICATION:



• Opioid Use Disorder (Moderate to Severe)

in patients who have initiated treatment with

- single dose of a transmucosal buprenorphine product or
- who are already being treated with buprenorphine











8 mg/0.16 mL

16 mg/0.32 mL

24 mg/0.48 mL

32 mg/0.64 mL

64 mg/0.18 mL

96 mg/0.27 mL

128 mg/0.36 mL

- Weekly doses cannot be combined to yield a monthly dose.
- Administer as a single injection. Do not divide.




DO NOT ADMINISTER
INTRAVENOUSLY,
INTRAMUSCULARLY, OR
INTRADERMALLY



Brixadi: Injection Site






- Administer: subcutaneously slowly
- Locations: subcutaneous tissue of the buttock, thigh, abdomen, or upper arm.
- Weekly Injections: should not be administered to the same site of injection X at least 8 weeks
 - Monthly Injections: No injection site rotation is required.





NOT CURRENTLY RECEIVING BUPRENORPHINE TREATMENT

WEEK 1



Subsequent Weekly Injections:

- based on the total weekly dose established during Week 1
- Dosage adjustments can be made at weekly appointments
- maximum weekly dose: 32 mg

Monthly Brixadi is not intended for patients who are not currently receiving buprenorphine treatment.






to either


weekly or


SWITCHING FROM TRANSMUCOSAL BUPRENORPHINE TO BRIXADI



18-24 mg

>>>>>









SWITCHING BETWEEN WEEKLY & MONTHLY BRIXADI



Brixadi (Weekly)

16 mg



64 mg

Brixadi

(Monthly)

24 mg



96 mg

32 mg



128 mg



Brixadi: Discontinuation




Brixadi (Weekly)

Brixadi (Monthly) STEADY STATE

REACHED IN

4 Weeks

4 Months



AFTER DISCONTINUATION:
DETECTABLE PLASMA LEVELS
FOR

1 Month


4 Months

Monitor for signs and symptoms of withdrawal for this duration & treat appropriate



Brixadi: Common Side Effects





Injection Site Pain Injection Site Erythema Injection Site Pruritus



Constipation



Nausea






UTI




Brixadi: Warnings & Precautions






Addiction, Abuse





Respiratory Depression





Neonatal Opioid Withdrawal Syndrome



BRIXADI: REMS PROGRAM



- Certification: Healthcare Settings and Pharmacies that order and dispense Brixadi must be certified in the BRIXADI REMS.
- Dispense to Healthcare Providers Only: Certified Healthcare Settings and Pharmacies must establish processes and procedures to verify BRIXADI is provided directly to a healthcare provider for administration by a healthcare provider, and the drug is not dispensed to the patient.
- Certified Healthcare Settings and Pharmacies must not distribute, transfer, loan, or sell BRIXADI.

www.BrixadiREMS.com

PSYCHIATRY EDUCATION FORUM'S

ACADEMY MEMBERSHIP

MOST UPDATED & UPGRADED VERSION OF EDUCATIONAL ACTIVITY PROVIDED BY PSYCHIATRY EDUCATION FORUM



JOIN AT: PSYCHIATRYEDUCATIONFORUM.COM